Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

2023-507654-33-00
Recruiting
MB-CART19.1 in refractory SLE
Phase 1/2 · Germany · 4 sites
Registry update: 15 Sept 2026
NCT06182969
Recruiting
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Phase 1/2 · China · 1 site
Registry update: 16 Dec 2025
NCT06434363
Recruiting
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Phase 1/2 · United States · 2 sites
Registry update: 3 Nov 2026
NCT06513429
Recruiting
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
Not applicable · China · 1 site
Registry update: 31 Aug 2026
NCT06400537
Recruiting
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Phase 1 · China · 2 sites
Registry update: 17 Sept 2025
NCT06497361
Recruiting
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
Early phase 1 · China · 1 site
Registry update: 11 Jul 2024
NCT06458075
Recruiting
Intervention to Improve Communication and Medication Adherence in Lupus
Not applicable · United States · 1 site
Registry update: 17 Aug 2026
NCT06497387
Recruiting
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
Early phase 1 · China · 1 site
Registry update: 11 Jul 2024
NCT06394063
Recruiting
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
Not applicable · China · 1 site
Registry update: 3 Jul 2024
NCT05799378
Recruiting
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Phase 3 · United States · 12 sites
Registry update: 20 Aug 2026
NCT06106906
Recruiting
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
Phase 1/2 · China · 1 site
Registry update: 8 Jan 2025
NCT06557265
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/2 · Australia, Puerto Rico, United States · 19 sites
Registry update: 4 Jun 2026
NCT05538208
Recruiting
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Phase 2 · United States · 19 sites
Registry update: 14 Sept 2026
NCT06428188
Recruiting
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1/2 · China · 1 site
Registry update: 5 Nov 2024
NCT06133972
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Phase 3 · Argentina, Australia, Bulgaria, Brazil, Canada, Chile, China, Colombia, Czechia, Germany, Spain, France, Guatemala, Hungary, Israel, India, Italy, Japan, South Korea, Mexico, Malaysia, Poland, Portugal, Romania, Slovakia, Thailand, Taiwan, United States, South Africa · 170 sites
Registry update: 9 Nov 2026
NCT06581562
Recruiting
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Phase 1 · United States · 1 site
Registry update: 3 Sept 2024
NCT06378736
Recruiting
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Not applicable · United States · 1 site
Registry update: 6 Nov 2026
NCT06503224
Recruiting
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Not applicable · China · 1 site
Registry update: 24 Apr 2025
NCT06308978
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Phase 1 · France, United Kingdom, Sweden, United States · 21 sites
Registry update: 22 May 2026
NCT06249438
Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1 · China · 1 site
Registry update: 25 Jul 2025

Ordered by registry start date. Freshness and sponsorship never change the order.